Search research articles
Contact Us
Filters
Showing results (1-10 of 464) with videos related to
Page
of 47
Sort By:
Neurodegenerative Disease Management
|
November 28, 2015
Physician-patient communication skills: e-tools
Tjalf Ziemssen
Neurology
|
November 7, 2022
Reader Response: NfL as Analogue of C-Reactive Protein in Neurologic Diseases: Instructions for Use
Tjalf Ziemssen
Advances in Experimental Medicine and Biology
|
February 24, 2004
Neuroprotection and glatiramer acetate: the possible role in the treatment of multiple sclerosis
Tjalf Ziemssen
Journal of Neurology
|
March 21, 2009
What can we learn from failed clinical trials in multiple sclerosis?
Tjalf Ziemssen
Journal of the Neurological Sciences
|
February 10, 2009
Multiple sclerosis beyond EDSS: depression and fatigue
Tjalf Ziemssen
Neurodegenerative Disease Management
|
January 19, 2019
Tetrahydrocannabinol: cannabidiol oromucosal spray for treating symptoms of multiple sclerosis spasticity: newest evidence
Tjalf Ziemssen
Journal of Neurology
|
October 29, 2005
Modulating processes within the central nervous system is central to therapeutic control of multiple sclerosis
Tjalf Ziemssen
Journal of the Neurological Sciences
|
December 31, 2011
Symptom management in patients with multiple sclerosis
Tjalf Ziemssen
Current Pharmaceutical Design
|
May 23, 2012
Psychoneuroimmunology - psyche and autoimmunity
Tjalf Ziemssen
International Review of Neurobiology
|
May 29, 2007
Glatiramer acetate: mechanisms of action in multiple sclerosis
Tjalf Ziemssen, Wiebke Schrempf
Page
of 47
Search research articles
Search
Showing results (1-10 of 464) with videos related to
Sort By:
Page
of 47
Neurodegenerative Disease Management
|
November 28, 2015
Physician-patient communication skills: e-tools
Tjalf Ziemssen
Neurology
|
November 7, 2022
Reader Response: NfL as Analogue of C-Reactive Protein in Neurologic Diseases: Instructions for Use
Tjalf Ziemssen
Advances in Experimental Medicine and Biology
|
February 24, 2004
Neuroprotection and glatiramer acetate: the possible role in the treatment of multiple sclerosis
Tjalf Ziemssen
Journal of Neurology
|
March 21, 2009
What can we learn from failed clinical trials in multiple sclerosis?
Tjalf Ziemssen
Journal of the Neurological Sciences
|
February 10, 2009
Multiple sclerosis beyond EDSS: depression and fatigue
Tjalf Ziemssen
Neurodegenerative Disease Management
|
January 19, 2019
Tetrahydrocannabinol: cannabidiol oromucosal spray for treating symptoms of multiple sclerosis spasticity: newest evidence
Tjalf Ziemssen
Journal of Neurology
|
October 29, 2005
Modulating processes within the central nervous system is central to therapeutic control of multiple sclerosis
Tjalf Ziemssen
Journal of the Neurological Sciences
|
December 31, 2011
Symptom management in patients with multiple sclerosis
Tjalf Ziemssen
Current Pharmaceutical Design
|
May 23, 2012
Psychoneuroimmunology - psyche and autoimmunity
Tjalf Ziemssen
International Review of Neurobiology
|
May 29, 2007
Glatiramer acetate: mechanisms of action in multiple sclerosis
Tjalf Ziemssen, Wiebke Schrempf
Page
of 47